High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Balance Sheet: Strong Balance Sheet.
Past Returns: In past three years, the stock has provided 16.4% return compared to 10.5% by NIFTY 50.
Growth: Good revenue growth. With 32.6% growth over past three years, the company is going strong.
Momentum: Stock price has a strong positive momentum. Stock is up 3.6% in last 30 days.
No major cons observed.
Valuation | |
|---|---|
| Market Cap | 3.01 kCr |
| Price/Earnings (Trailing) | 62.11 |
| Price/Sales (Trailing) | 3.33 |
| EV/EBITDA | 24.08 |
| Price/Free Cashflow | 75.73 |
| MarketCap/EBT | 43.21 |
| Enterprise Value | 3.28 kCr |
Fundamentals | |
|---|---|
| Revenue (TTM) | 904.28 Cr |
| Rev. Growth (Yr) | 10.6% |
| Earnings (TTM) | 52.18 Cr |
| Earnings Growth (Yr) | -19.4% |
Profitability | |
|---|---|
| Operating Margin | 8% |
| EBT Margin | 8% |
| Return on Equity | 8.3% |
| Return on Assets | 4.11% |
| Free Cashflow Yield | 1.32% |
Growth & Returns | |
|---|---|
| Price Change 1W | 4% |
| Price Change 1M | 3.6% |
| Price Change 6M | -17.8% |
| Price Change 1Y | -3.2% |
| 3Y Cumulative Return | 16.4% |
| 5Y Cumulative Return | 21.1% |
| 7Y Cumulative Return | 21.4% |
| 10Y Cumulative Return | 21.9% |
Cash Flow & Liquidity | |
|---|---|
| Cash Flow from Investing (TTM) | -70.78 Cr |
| Cash Flow from Operations (TTM) | 122.57 Cr |
| Cash Flow from Financing (TTM) | -37.2 Cr |
| Cash & Equivalents | 74.6 Cr |
| Free Cash Flow (TTM) | 47.04 Cr |
| Free Cash Flow/Share (TTM) | 4.69 |
Balance Sheet | |
|---|---|
| Total Assets | 1.27 kCr |
| Total Liabilities | 639.94 Cr |
| Shareholder Equity | 628.55 Cr |
| Current Assets | 727.21 Cr |
| Current Liabilities | 469.64 Cr |
| Net PPE | 488.7 Cr |
| Inventory | 229.66 Cr |
| Goodwill | 0.00 |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.27 |
| Debt/Equity | 0.55 |
| Interest Coverage | 0.96 |
| Interest/Cashflow Ops | 5.42 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 0.1 |
| Dividend Yield | 0.03% |
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | 3.4% |
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Balance Sheet: Strong Balance Sheet.
Past Returns: In past three years, the stock has provided 16.4% return compared to 10.5% by NIFTY 50.
Growth: Good revenue growth. With 32.6% growth over past three years, the company is going strong.
Momentum: Stock price has a strong positive momentum. Stock is up 3.6% in last 30 days.
No major cons observed.
Investor Care | |
|---|---|
| Dividend Yield | 0.03% |
| Dividend/Share (TTM) | 0.1 |
| Shares Dilution (1Y) | 0.00% |
| Earnings/Share (TTM) | 4.83 |
Financial Health | |
|---|---|
| Current Ratio | 1.55 |
| Debt/Equity | 0.55 |
Technical Indicators | |
|---|---|
| RSI (14d) | 57.85 |
| RSI (5d) | 88.7 |
| RSI (21d) | 58.41 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Hold |
| SharesGuru Signal | Buy |
| RSI Signal | Hold |
| RSI5 Signal | Sell |
| RSI21 Signal | Hold |
| SMA 5 Signal | Buy |
| SMA 10 Signal | Buy |
| SMA 20 Signal | Buy |
| SMA 50 Signal | Buy |
| SMA 100 Signal | Buy |
Summary of Gufic BioSciences's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Understand Gufic BioSciences ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| Jayesh Pannalal Choksi | 24.62% |
| Zircon Teconica Private Limited | 20.47% |
| Gufic Private Limited | 10.16% |
| Vipula Jayesh Choksi | 10.01% |
| Pranav Jayesh Choksi | 7.25% |
| Motilal Oswal Financial Services Limited | 3.32% |
| ICICI Prudential Multicap Fund | 2.03% |
| Jagdish N Master | 1.43% |
| Pooja Pranav Choksi | 0% |
| Meira Pranav Choksi | 0% |
| Shiv Pranav Choksi | 0% |
| Rita Ashok Shah | 0% |
| Kshama Vipul Choksi | 0% |
| Forum Ameet Shah | 0% |
| Jayesh Pannalal Choksi (HUF) | 0% |
| Uma Lalit Trivedi | 0% |
| Dhan Pankaj Zaveri | 0% |
| Deepika Milan Barot | 0% |
| Pankaj Ramniklal Pandya | 0% |
| Jagdeep Ramniklal Pandya | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
Detailed comparison of Gufic BioSciences against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| DIVISLAB | Divi's Lab | 1.58 LCr | 10.75 kCr | -6.60% | +10.50% | 63.75 | 14.7 | - | - |
| AUROPHARMA | Aurobindo Pharma | 77.85 kCr | 33.73 kCr | +4.20% | +26.70% | 22.33 | 2.31 | - | - |
| NATCOPHARM | Natco Pharma | 20.13 kCr | 4.85 kCr | +8.10% | +50.50% | 12.93 | 4.15 | - | - |
| GRANULES | Granules India | 15.42 kCr | 5.11 kCr | +9.30% | +47.40% | 28.27 | 3.02 | - | - |
| STAR | STRIDES PHARMA SCIENCE | 9.18 kCr | 4.88 kCr | +14.10% | +70.50% | 17.95 | 1.88 | - | - |
Comprehensive comparison against sector averages
GUFICBIO metrics compared to Pharmaceuticals
| Category | GUFICBIO | Pharmaceuticals |
|---|---|---|
| PE | 62.11 | 33.71 |
| PS | 3.33 | 4.65 |
| Growth | 11.1 % | 8 % |
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments. In addition, the company offers criti care, criticare life, ferticare, and spark pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. It supplies its products to hospital chains and medical facilities. The company was founded in 1970 and is based in Mumbai, India.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
GUFICBIO vs Pharmaceuticals (2021 - 2026)